

Scorecard for Osteoporosis in Europe

	Austria	Belgium	Bulgaria	Cyprus	Czech Republic	Denmark	Estonia	Finland	France	Germany	Greece	Hungary	Ireland	Italy	Latvia	Lithuania	Luxembourg	Malta	Netherlands	Poland	Portugal	Romania	Slovakia	Slovenia	Spain	Sweden	UK	Description	Units	Score				
Burden of disease																																		
Hip fracture risk	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	Age-standardised incidence of hip fracture in women	rate/100,000	<300	300-400	400+	unknown
Fracture risk	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	All osteoporotic fractures in men and women	rate/1000 >50 years	<15	15-20	>20	
Lifetime risk	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	Lifetime risk of hip fracture (women aged 50y)	%	<13	13-18	>18	unknown
FRAX risk	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	Men and women with a > 10% ten year probability of a major fracture	% in 50-89 years age range	<20	20-25	>25	
Fracture projections	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	Increase in fracture number 2010-2025	% >50 years	0-25	26-33	>30		
Policy framework																																		
Quality of data	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	Data on hip fracture rates	Score	-	-	-		
National health priority	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	The presence of government backed NHP	Score	-	-	-		
Care pathway	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	Management in primary care	Score	-	-	-		
Specialist training	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	Osteoporosis an established specialty.	Score	-	-	-		
Society support	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	Patient support societies	Score	-	-	-		
Service provision																																		
Treatment	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	Reimbursement and problems that arise	Score	-	-	-		
Availability of DXA	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	DXA units available	Units/m of the general population	>18	8.4-18	<8.4		
Access to DXA	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	Reimbursement and problems that arise	Score	-	-	-		
Risk models	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	Availability of country-specific risk models and guidance	Score	-	-	-		
Guideline quality	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	Quality and scope of guidelines for assessment and treatment	Score	-	-	-	none	
Liaison service	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	Provision for fracture liaison services	Score	-	-	-	unknown		
Quality indicators	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	Presence and use of quality indicators	Score	-	-	-			
Service uptake																																		
Risk models	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	FRAX calculations	/million of the general population/year	>1200	320-1200	<320		
Treatment gap	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	Proportion of women at high risk who are untreated	% >50 years	<45	45-65	>65	unknown	
Waiting time	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	Average waiting time for hip surgery	days	<1	1-2	>2	unknown	